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REVISION 28 
 29 
ABSTRACT 30 
 31 
Sub-optimal recovery of bacterial DNA from whole blood samples can limit the sensitivity of 32 
molecular assays to detect pathogenic bacteria.  We compared 3 different pre-lysis protocols (none, 33 
mechanical pre-lysis and achromopeptidase pre-lysis) and 5 commercially available DNA extraction 34 
platforms for direct detection of Group B Streptococcus (GBS) in spiked whole blood samples, 35 
without enrichment culture. DNA was extracted using the QIAamp Blood Mini kit (Qiagen), UCP 36 
Pathogen Mini kit (Qiagen), QuickGene DNA Whole Blood kit S (Fuji), Speed Xtract Nucleic Acid 37 
Kit 200 (Qiagen) and MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche Diagnostics Corp). 38 
Mechanical pre-lysis increased yields of bacterial genomic DNA by 51.3 fold (95% confidence 39 
interval; 31.6 - 85.1, p<0.001) and pre-lysis with achromopeptidase by 6.1 fold (95% CI; 4.2 - 8.9, 40 
p<0.001), compared with no pre-lysis.  Differences in yield due to pre-lysis were 2-3 fold larger than 41 
differences in yield between extraction methods. Including a pre-lysis step can improve the limits of 42 
detection of GBS using PCR or other molecular methods without need for culture. 43 
 44 
INTRODUCTION 45 
 46 
Streptococcus agalactiae (Lancefield Group B streptococcus [GBS]) is the most common cause of 47 
serious bacterial illness in neonates.  Incidence of GBS disease in neonates less than 90 days old is 48 
0.43 per 1000 births, with a case fatality of 12% (1). Conventional detection of GBS from patient 49 
samples using culture is both time-consuming and unreliable, particularly if samples are taken after 50 
antibiotics are administered (2). Laboratory diagnosis involves culture of recto-vaginal swab samples 51 
(when screening for antepartum or intrapartum carriage) and culture of blood and/or cerebrospinal 52 
fluid (CSF) samples from unwell neonates or neonates known to have been exposed to maternal GBS 53 
(3).  Effective molecular tests for GBS would be valuable to clinicians by obviating the need for 54 
 3 
several days of culture. Several quantitative real-time polymerase chain reaction (PCR) assays for 55 
GBS have been developed and validated, most for use on vaginal swab samples rather than whole 56 
blood (4-7).  One recent study showed a real-time PCR assay to detect the cylB gene in blood and/or 57 
CSF was significantly more sensitive than culture for diagnosis of GBS infection in neonates (2). 58 
 59 
Effective DNA extraction from clinical specimens is critical for molecular pathogen detection. This is 60 
particularly the case for whole blood, where the complex matrix and presence of PCR inhibitors can 61 
make DNA extraction difficult (8, 9).  It is well established that different methods of sample 62 
preparation and DNA extraction have a significant impact on overall assay sensitivity (10, 11).  GBS is 63 
a Gram-positive organism with a robust cell wall, and accordingly it can be difficult to lyse bacterial 64 
cells to release genomic DNA (9).  This makes molecular detection of GBS much more challenging 65 
than, for example, Neisseria meningitidis (an easily-lysed Gram-negative organism) where PCR 66 
testing is widely recognised as a gold standard method (12, 13). 67 
 68 
Molecular testing of neonatal blood and/or CSF specimens may improve the diagnosis of early-onset 69 
sepsis caused by GBS, as detection of GBS DNA in a sterile site specimen would confirm the 70 
diagnosis. However, failure to lyse GBS cells will adversely affect detection limits and clinical 71 
sensitivity of molecular GBS tests. This study aimed to optimise extraction of GBS DNA from whole 72 
blood, and to improve detection limits for molecular GBS detection. We report data from three 73 
different pre-lysis methods and five different DNA extraction kits on the yield of GBS DNA from 74 
spiked samples of saline and whole blood. Significant differences in yield were observed using 75 
different extraction methods, with exceptionally low yields seen when commonly used extraction kits 76 
were used without pre-lysis. 77 
  78 
 4 
METHODS 79 
 80 
Preparation of GBS-spiked samples 81 
 82 
Streptococcus agalactiae (strain ATCC 12386) was cultured overnight on Columbia Blood Agar 83 
(CBA) at 37°C in a 10% CO2 atmosphere and resuspended in sterile phosphate buffered saline (PBS) to 84 
an optical density of ~1.5. Tenfold serial dilutions were prepared with the number of colony forming 85 
units per ml (CFU.ml-1) ascertained by the spread plate method (14). Triplicate aliquots (100μl) of 86 
duplicate serial dilutions were plated onto CBA plates. Following overnight incubation at 37°C in 10% 87 
CO2 atmosphere individual colonies were counted and the mean CFU.ml-1 count determined. Aliquots 88 
(200μl) of the GBS suspension were stored at –20°C until required. Each aliquot of GBS cells 89 
underwent one freeze-thaw cycle only. Aliquots (2.8ml) of sterile PBS or whole EDTA-treated human 90 
blood were inoculated with cell suspension (200μl) containing either 6.3 × 104 cfu.μl-1 (“high spike” 91 
sample) or 63 cfu.μl-1 (“low spike” sample) prior to DNA extraction. 92 
 93 
Sample pre-lysis protocols 94 
 95 
Two protocols for sample pre-lysis prior to DNA extraction were compared: enzymatic lysis using 96 
achromopeptidase (ACH, lysyl endopeptidase, EC 3.4.21.50) and mechanical lysis using bead-beating. 97 
Controls were extracted without any pre-lysis. 98 
 99 
For enzymatic lysis, ACH (100kU; Sigma-Aldrich, Gillingham, U.K.) was dissolved in 5.2ml of Tris-100 
EDTA buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0). Sample aliquots (200μl) were mixed with an 101 
equal volume of ACH stock (200μl, containing 3.85kU ACH) and incubated at room temperature 102 
(22°C) for 5 minutes. For spiked saline samples, ACH was inactivated prior to extraction by heating to 103 
95°C for 5 minutes. Preliminary experiments found the efficiency of ACH lysis in EDTA-blood was 104 
significantly reduced compared to lysis in saline (data not shown). Dilution (1:4) with Tris-HCl buffer 105 
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(10mM, pH 8.0) prior to ACH treatment resolved this, so blood samples were diluted before addition 106 
of ACH and incubation. For blood samples, instead of heating (which caused blood to clot), ACH was 107 
inactivated prior to extraction by addition of lysis buffer from the extraction kit being evaluated. 108 
 109 
For mechanical lysis, samples were processed by bead-beating using Pathogen Lysis Tubes S (Qiagen, 110 
Manchester, UK). Saline or blood (400μl) spiked with GBS cells were mixed with lysis buffer (100μL) 111 
containing anti-foam Reagent DX (0.67% v/v) in a Lysis Tube. The recommended lysis buffer for each 112 
extraction protocol being evaluated was used (Qiagen Buffer ATL, Fuji Buffer LDB or Roche Lysis 113 
Buffer). Bead beating was done using a Mini-BeadBeater-1 (Biospec Products Inc., Bartlesville, USA) 114 
on full speed for 90 seconds. 115 
 116 
DNA extraction protocols 117 
 118 
Following sample pre-lysis, five different DNA extraction kits were compared (Table 1): QIAamp 119 
Blood Mini kit (Qiagen); QIAamp UCP Pathogen Mini kit (Qiagen); QuickGene DNA Whole Blood 120 
kit S (Fuji); MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche Diagnostics Corp., 121 
Indianaopolis, US); and SpeedXtract Nucleic Acid Kit 200 (Qiagen). Each kit was used according to 122 
the manufacturers’ instructions, with one exception. The SpeedXtract kit uses two rounds of binding 123 
onto magnetic beads, leaving the target DNA in solution after the second magnetic separation. The 124 
protocol was modified to include ACH pre-lysis between the two magnetic separations, prior to 125 
removal of the magnetic beads. Buffer EN (400μl) was added to spiked EDTA whole blood (200μl) 126 
and incubated with SpeedXtract Suspension A magnetic beads, according to the manufacturer’s 127 
protocol for liquid samples.  Following magnetic separation, removal of supernatant and a wash step 128 
using Buffer EN, the Suspension A beads were resuspended in ACH (100μl) and incubated at room 129 
temperature for 5 minutes followed by heating to 95°C for 5 minutes. After ACH treatment, Buffer SL 130 
(100μl) was added and samples were heated again to 95°C for 5 minutes before completing the 131 
manufacturer’s protocol.  Controls were extracted without ACH by resuspending the Suspension A 132 
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magnetic beads in Buffer SL (200μl) and heating to 95°C for 10 minutes. It was not feasible to 133 
incorporate bead-beating into the SpeedXtract protocol without major deviation from the 134 
manufacturer’s protocol. Bead-beating would either lyse bacterial cells in blood prior to the first 135 
magnetic separation (with loss of the bacterial DNA) or would require bead-beating of the magnetic 136 
particles prior to the second magnetic separation (with possible mechanical breakdown of the 137 
particles). 138 
 139 
The QIAamp UCP Pathogen kit was not evaluated without pre-lysis or using ACH pre-lysis, as the 140 
manufacturer’s protocol specifies bead-beating. Conversely, bead-beating was not evaluated for the 141 
QIAamp Blood Mini kit because the extraction chemistry is identical to the QIAamp UCP Pathogen 142 
kit. Data from these two kits were therefore combined as a single “Qiagen column” method for 143 
comparison with other methods. For both QIAamp kits, extraction columns were processed by 144 
centrifugation, according to the manufacturer’s instructions. For Fuji and Roche methods, the 145 
QuickGene Mini-80 and MagNA Pure Compact systems were used respectively. Following extraction, 146 
purified DNA was eluted using the manufacturers’ elution buffer for each kit. Elution volume was 147 
100μl for all methods, except SpeedXtract where 200μl elution was used.  Combinations of different 148 
sample pre-lysis and extraction methods introduced different overall dilution factors (Table S1), so 149 
appropriate corrections were required for calculation of yield. 150 
 151 
Reference DNA extraction and quantification 152 
 153 
Genomic  DNA was extracted from a suspension of S. agalactiae ATCC 12386 in PBS, using the 154 
Roche MagNA Pure method with pre-lysis using both ACH and bead-beating. DNA concentration was 155 
determined using a NanoDrop™ 2000 UV spectrophotometer (ThermoFisher Scientific Inc., Waltham, 156 
USA) and genome copy number per μl calculated assuming a genome size of 2.13 x 106 bp (S. 157 
agalactiae A909 whole genome; RefSeq NC_007432). Calibrators for qPCR were prepared by dilution 158 
of the reference DNA stock in Tris-HCl buffer (1mM, pH 8.0) containing 0.1 μg.μl-1 yeast tRNA 159 
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(Sigma-Aldrich, Gillingham, U.K.). Ten-fold serial dilutions over a 6 log range were prepared for 160 
qPCR calibration and to evaluate limits of detection.  161 
 162 
Real-time quantitative PCR (qPCR) 163 
 164 
A previously published Taqman® qPCR assay targeting the sip gene was used to detect and quantify 165 
GBS DNA (7). Primers and probe were synthesised by Eurogentec (Eurogentec, Liège Belgium). The 166 
probe was labelled with 5'-FAM and 3'-Black Hole Quencher 1. The final qPCR reaction mix 167 
contained 1X Platinum® UDG Mastermix (Thermo Scientific, Manchester, UK), 0.2µM Bovine serum 168 
albumin (Sigma, Dorset, UK),  4 mmol.L-1 MgCl2, 0.4µM forward and reverse primers, 0.2µM probe, 169 
Nuclease Free Water (Promega, Southampton, UK) and 3µl of target template for a final reaction 170 
volume of 12µl. qPCR was performed using a Light Cycler 480 (LC480) instrument (Roche 171 
Diagnostics, Mannheim, Germany) using the following thermal cycling program: 95°C (10 minutes) 172 
followed by 45 cycles of 95°C (10 seconds) / 60°C (1 minute), with fluorescence acquisition at the end 173 
of each extension cycle.  Data were analysed using LC480 software and GBS genome copy number for 174 
positive specimens determined from crossing point threshold (Cp) relative to an external calibration 175 
curve, prepared as described above, with triplicate assays run on duplicate dilution series. Calibrators 176 
and no-template (water) controls were also run with each batch of qPCR samples. PCR efficiency (% 177 
efficiency = [10(-1/slope)–1] × 100) and linearity were evaluated by linear regression of log-transformed 178 
calibration data. Data were analysed in Excel 2011 (Microsoft Corp., Seattle, USA) and Stata 11 (Stata 179 
Corp., Texas, USA). 180 
 181 
Data from the “high spike” samples are presented for numerical comparisons of yield, with 95% 182 
confidence intervals (95% CI), whereas data from the “low spike” samples served to delineate the 183 
lower limits of detection.  Numerical comparison of yield for the “low spike” samples was not feasible 184 
because the yield for many of the methods was so low that many (or all) replicates were negative for 185 
GBS DNA when tested. Genome copy number data are shown for all PCR-positive samples.  186 
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RESULTS 187 
 188 
Performance of qPCR assay 189 
 190 
Efficiency of the sip gene qPCR, calculated from calibrator dilutions over a 6 log range (from 35 191 
genome copies to 3.5 × 106 genome copies per reaction) was 100.3% with very high linearity (R2 = 192 
0.999), indicating the assay had excellent dynamic performance. The lower limit of detection for the 193 
assay was found to be 7 genome copies per reaction, as 5/5 replicate assays were positive at that level 194 
of dilution. Copy numbers below 7 per reaction were not evaluated. 195 
 196 
Reference DNA extraction method 197 
 198 
The highest yields of genomic DNA were obtained by using combined ACH and mechanical pre-lysis 199 
of stock GBS suspensions in PBS, followed by MagNA Pure extraction. Genome copy numbers 200 
recovered from PBS using this method were 5.5× higher than expected copy numbers calculated from 201 
viable count (cfu/ml) data for the GBS spike. This was presumably due to the presence of non-viable 202 
and non-culturable cells and chains of GBS cells in the spiked samples, making culture-based 203 
estimates of copy number inaccurate. The analytical performance of the qPCR assay meant reliable 204 
estimates of genome copy number could be obtained, but only post-extraction. These estimates 205 
probably still underestimate the actual genome copy number in the spike, as the yield of the reference 206 
extraction method is unlikely to be 100%. The yields of genomic DNA using other extraction methods 207 
(each quantified using qPCR, as absolute genome copy numbers) were calculated relative to this 208 
reference extraction method, and presented as “expected genome copies per ml”. 209 
 210 
As determined by reference extraction of aliquots of GBS cells suspension in PBS (using combined  211 
bead-beating, ACH treatment and MagNA Pure extraction) there were 1.84 × 107 (95% CI 4.4 × 106 – 212 
2.3 × 107) genome copies per ml of high spike EDTA blood and 1.68 × 104 (95% CI 9.8 × 103 – 2.1 × 213 
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104) genome copies per mL of low spike blood.  Expected copies per PCR reaction (3μl aliquot from a 214 
100μl or 200μl DNA extract) varied from 9.4 × 103 to 1.7 × 105 copies in the case of high spike 215 
samples, and 9 to 152 copies in the case of low spike samples, depending on the dilution factor 216 
involved in pre-lysis and extraction (Table S1). 217 
 218 
Comparison of different pre-lysis and extraction protocols. 219 
 220 
Figure 1 summarises the differences in absolute yield of gDNA in the high-spike experiments, 221 
according to extraction protocol.  Table 2 shows percentage yield of each extraction, relative to the 222 
reference method, after taking into account the different dilution factors involved. 223 
 224 
The overall effect of mechanical pre-lysis in the high spike samples was to increase yields of DNA by 225 
51.3 fold (95% CI; 31.6 – 85.1 fold, p<0.001) compared with no pre-treatment.  Pre-lysis with ACH 226 
increased yields by 6.1 fold (95% CI; 4.2 – 8.9 fold, p<0.001).   In preliminary experiments we found 227 
that ACH treatment is ineffective in undiluted whole blood, and that a 1 in 4 dilution prior to ACH 228 
treatment is optimal for maximal yield (data not shown). This introduces an unavoidable dilution step 229 
in the ACH pre-lysis protocol for whole blood, compared with mechanical lysis (Table S1). Treatment 230 
with ACH was slightly superior to mechanical lysis in terms of increased % recovery of DNA (1.8 fold 231 
greater percentage recovery of DNA, p=0.020) but because the ACH pre-lysis protocol required more 232 
sample dilution, the mechanical pre-lysis protocol gave higher overall higher yields of DNA. 233 
 234 
There was no significant difference in DNA yield between the Qiagen and Fuji column-based 235 
extraction methods (p=0.238). The MagNA Pure extraction method gave the highest absolute yield of 236 
DNA, giving 1.96 fold greater yield than the column-based extraction methods (95% CI; 1.26 to 3.07 237 
fold, p=0.004).  The SpeedXtract system preformed slightly less well. The spin-column based methods 238 
gave a yield 2.41 fold greater than the SpeedXtract kit (95% CI; 0.74 to 4.31 fold, p=0.004), although 239 
the SpeedXtract protocol was the simplest, requiring only a magnetic rack. 240 
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 241 
Lower limits of detection 242 
 243 
In the “low spike” experiments we investigated the lower limits of detection for GBS in whole blood 244 
samples. Based on preliminary experiments the GBS load in these blood samples (1.68 × 104 genome 245 
copies.mL-1) was expected to be at or below the limits of detection using some extraction methods 246 
(data not shown). Due to the very low copy numbers expected, additional replicates were included in 247 
these experiments.  248 
 249 
Firstly, results were compared based on pre-lysis method. In low spike samples without any pre-lysis, 250 
8/25 (32%) were positive for GBS DNA, with a mean genome copy number of 3.8 (95% CI; 3.0 – 4.5) 251 
copies per reaction in positive samples. In samples with mechanical pre-lysis, 18/18 (100%) were 252 
positive for GBS DNA, with a mean copy number of 58.1 (95% CI; 42.2 – 74.0) copies per reaction.  253 
In samples with ACH pre-lysis, 16/34 (47%) were positive for GBS, with a mean copy number of 19.6 254 
(95% CI; 5.3 – 33.8) copies per reaction. Of note, in the low-spike samples using the ACH pre-lysis 255 
protocol, 6/6 (100%) replicates extracted using the SpeedXtract system were positive for GBS DNA.  256 
This compares to 5/10 (50%) using Qiagen Blood Amp Mini kit, 2/10 (20%) using the Fuji QuickGene 257 
and 3/8 (37.5%) using MagNA Pure.  As previously stated, ACH pre-lysis required a 1 in 4 dilution of 258 
whole blood.  The chemistry of the Speed Xtract kit is different from the other kits; the supernatant 259 
containing most of the whole blood components is discarded early in the process following magnetic 260 
separation. It was not possible to incorporate mechanical pre-lysis into this protocol, but ACH could be 261 
used without an additional dilution step which may explain the superior performance. 262 
 263 
Secondly, we compared the effects of extraction platform using samples without any pre-lysis (i.e. 264 
exactly according to manufacturer’s protocol). GBS DNA was detected in: 3/6 (50%) replicates 265 
extracted using the Qiagen Blood Mini Kit with a mean of 3.6 (95% CI; 0.9 – 6.3) genome copies per 266 
reaction; 3/6 (50%) replicates extracted with the Speed Xtract kit with a mean of 3.7 (95% CI; 0.7 – 267 
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6.7) genome copies per reaction; and 0/6 (0%) replicates extracted with the Fuji Quickgene extraction 268 
platform. GBS DNA was detected in 2/7 (28.6%) replicates where samples were extracted using the 269 
MagNA Pure system, with a mean of 4.1 (95% CI; 3.3 – 4.9) genome copies per reaction. 270 
 271 
Discussion 272 
 273 
In this study, we found yields of S. agalactiae genomic DNA from blood, using several different 274 
commercial DNA extraction kits, were extremely low. Unsurprisingly, much higher yields were seen 275 
when kits were modified to include mechanical lysis, although the improvements using a very simple 276 
and rapid enzyme treatment were also impressive. To our knowledge, no previous studies have 277 
demonstrated use of ACH to improve lysis of S. agalactiae, or use of this enzyme at room 278 
temperature. We also used higher ACH unit activities than reported for other Gram-positive bacteria. 279 
Previous studies used arbitrary and varying amounts of ACH: 1000U/ml (18), 1500U/ml (15), 280 
2000U/ml (16) or 4000U/ml (19). Using 4000U/ml, Niwa et al (19) reported complete lysis of a range 281 
of Gram-positive bacteria in 10-15 minutes at 37ºC. Our method further increased the quantity of ACH 282 
(to 9625U/ml) in a simple, fast (5 minute) room temperature protocol. There may be scope to further 283 
improve yields by extending the incubation time, increasing the incubation temperature, or both. 284 
 285 
Large differences in yield from the high-spike samples were seen between different extraction methods 286 
using the same pre-lysis protocol. With no pre-lysis, or using bead-beating, both the Quickgene and 287 
MagNA Pure methods consistently gave better performance than the Qiagen method. Using ACH pre-288 
lysis, the yield for the Quickgene method was significantly reduced. The reasons for this are unclear. 289 
Comparing all 3 pre-lysis protocols, the MagNA Pure method was the most effective overall. This 290 
justified use of this method, with combined pre-lysis using both ACH and bead-beating, as the 291 
reference method for estimation of genome copy number in the spiked samples, and for yield 292 
calculations. The yields were lowest for extraction of the high-spike samples using the SpeedXtract 293 
method. However, the strong performance of this method for extraction of low-spike samples (due to 294 
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the smaller dilution factors involved) should be emphasised. This method is attractive in practical 295 
terms, and ACH pre-lysis did increase yield, so additional work to optimise this approach for GBS 296 
testing may be worthwhile.  297 
 298 
In terms of cost, the requirement for an automated extraction system (i.e. a MagNA Pure Compact or 299 
MagNA Pure 96 instrument) makes the MagNA Pure method significantly more expensive overall 300 
than the other methods. The reagent cost for MagNA Pure extractions was also the highest 301 
(£5.46/sample), while the SpeedXtract method was the least expensive (£1.57/sample). The reagents 302 
for the Quickgene (£2.78/sample) and the Qiagen Blood Mini (£2.68/sample) and Qiagen UCP 303 
(£3.34/sample) were intermediate in cost. The additional costs for pre-lysis were similar, at 304 
£2.58/sample for bead-beating and £2.46/sample for ACH. The overall extraction cost for the tested 305 
combinations with pre-lysis ranged from £4.03 to £10.50 per sample, excluding instrument costs. The 306 
optimum method in terms of both cost and performance was bead-beating with Quickgene extraction 307 
(£5.36/sample). 308 
 309 
Conventional culture methods for detection of Group B streptococcus are time consuming, and can be 310 
unreliable.  It has previously been shown that molecular methods can be used to detect GBS in culture-311 
negative EDTA-blood samples, although at a low rate; 2/35 culture-negative blood samples of babies 312 
with probable sepsis were positive by PCR (2). As Qiagen Blood Mini kits were used to extract DNA 313 
from samples without any pre-lysis in that study, our results suggest that poor DNA recovery may 314 
have limited the sensitivity of PCR. 315 
 316 
Recovering Gram-positive bacterial DNA from whole blood samples without a culture enrichment step 317 
remains a challenge. The utility of direct PCR in addition to culture to detect septicaemia and 318 
meningitis is well established for meningococcal septicaemia (12) , and PCR may become the gold 319 
standard method for many other invasive bacterial infections, provided that optimised extraction 320 
methods are used. 321 
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 322 
We found that processing samples with ACH or mechanical pre-lysis significantly increases the yield 323 
of GBS DNA with a mean increase of 6.1 fold and 51.3 fold respectively, after allowing for different 324 
dilution factors for different protocols.  The ACH pre-lysis method is straightforward, amenable to 325 
high-throughput or routine use, and the enzyme retains lytic activity for GBS for 30 days when stored 326 
at 4°C (data not shown).  Although more effective overall, and requiring no dilution step, the 327 
mechanical pre-lysis protocol requires a bead beating instrument and involves more hands-on sample 328 
preparation time.  329 
 330 
There is growing clinical interest in the use of rapid molecular tests to detect GBS in late pregnancy, 331 
especially during labour, and in near-patient settings. Intrapartum screening of all pregnant women for 332 
GBS using rapid molecular methods was recommended following a European consensus conference in 333 
2015 (20). However, sub-optimal recovery of GBS DNA from clinical specimens is a potentially 334 
important confounding factor that could affect the outcome of clinical trials in this area. A recent study 335 
in France (21) concluded that intrapartum PCR testing could improve diagnosis and prevention of 336 
GBS disease, compared to culture-based screening earlier in pregnancy. The study did not directly 337 
compare the analytical performance of PCR to intrapartum culture, although a separate French study in 338 
a different hospital (22) reported the sensitivity of intrapartum GBS PCR, compared to broth 339 
enrichment culture, was 94.4%. A Japanese study (23) concluded that intrapartum PCR testing for 340 
GBS was effective, although sensitivity was only 83.3% compared to broth enrichment culture on 341 
specimens collected at the same time. 342 
 343 
Our data suggest that problems with DNA extraction efficiency could adversely affect the performance 344 
of molecular tests to detect GBS in clinical specimens, leading to underestimation of both analytical 345 
and clinical sensitivity, and systematic bias in clinical trials. Unless this issue is properly evaluated and 346 
addressed, these problems might limit the clinical utility of these potentially very important testing 347 
methods for rapid detection of GBS in intrapartum screening and diagnosis of neonatal infections. 348 
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Legends 356 
 357 
Table1. 358 
Sample pre-lysis and extraction methods evaluated in this study. 359 
 360 
Table 2. 361 
Yield of GBS genomic DNA from “high spike” saline and blood samples (1.84 x 107 genome 362 
copies.ml-1). 363 
 364 
Figure 1. 365 
Box plot showing recovery of GBS genomic DNA from “high spike” saline and blood samples (1.84 x 366 
107 genome copies. ml-1). A: reference extractions from PBS; B: blood extraction, no pre-lysis; C: 367 
blood extraction, bead-beating pre-lysis; D: blood extraction, ACH pre-lysis. Abbreviations: nil = no 368 
pre-lysis; ACH = pre-lysis with achromopeptidase; BB = bead-beating pre-lysis.  369 
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Table1. Sample pre-lysis and extraction methods evaluated in this study 
 DNA extraction 
kit 
Pre-lysis method1 
None ACH Bead-beating 
Q
ia
ge
n 
co
lu
m
ns
 QIAamp Blood 
Mini + + – 
QIAamp UPC 
Pathogen Mini – – + 
 QuickGene DNA 
Whole Blood S + + + 
MagNA Pure 
Compact + + + 
SpeedXtract 
 + + – 
1 Some combinations could not be evaluated for technical reasons; see text for details. 
 
Table 2. Yield of GBS genomic DNA from “high spike” saline and blood samples (1.84 x 107 
genome copies.ml-1). 
Pre-lysis Extraction 
platform 
Expected 
copies per 
reaction 
Mean copies detected 
per reaction (±SE) 
Yield 
(%) 
Saline: 
ACH & bead-
beating* 
MagNApure 5.53 x 104 5.53 x 104 (±9410) 100% 
None MagNApure 1.10 x 105 2160 (±929) 1.95% 
EDTA-whole blood: 
None QIAamp Blood Mini 1.10 x 105 503 (±132) 0.46% 
None QuickGene Mini-80 1.10 x 105 480 (±332) 0.43% 
None MagNApure 5.53 x 104 792 (±336) 1.43% 
None SpeedXtract 5.53 x 104 247 (±50) 0.45% 
Bead-beating  UCP Pathogen Mini 1.66 x 105 1.55 x 104 (±6410) 9.34% 
Bead-beating  QuickGene Mini-80 5.53 x 104 4.35 x 104 (±2.79 x 104) 26.2% 
Bead-beating  MagNApure 1.10 x 105 3.54 x 104 (±9570) 32.0% 
ACH QIAamp Blood Mini 1.38 x 104 5240 (±1978) 37.9% 
ACH QuickGene Mini-80 1.38 x 104 1800 (±1390) 13.1% 
ACH MagNApure 9400 7190 (±3220) 76.4% 
ACH SpeedXtract 5.53 x 104 804 (±211) 1.45% 
* Reference extraction 
